BioSapien

BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline of indications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.

BioSapien headquartered in New York, New York, United States, North America, operates in the 3D Technology, Biotechnology, Pharmaceutical, Biopharma, 3D Printing sector. The company focuses on 3D Technology and has secured $5.9B in funding across 160 round(s). With a team of 1-10 employees, BioSapien is actively contributing to advancements in 3D Technology. Their latest funding round, Grant - BioSapien, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.